S pneumoniae infection treatment: DCGI nod to Biological E 14-valent paediatric Pneumococcal Conjugate Vaccine
BE’s PCV14 is comparable in terms of serotype coverage for infants to the two globally approved pneumococcal conjugate vaccines Prevenar13 and Merck’s VAXNEUVANCE.;
Hyderabad: Hyderabad-based Pharmaceutical and Vaccine Company, Biological E. Limited (BE), has announced that its 14-valent paediatric Pneumococcal Conjugate Vaccine, (Investigational Pneumococcal Polysaccharide Conjugate Vaccine PCV14) against S. pneumoniae infection has received approval from the Drugs Controller General of India (DCGI) for manufacture and commercialisation in India.
PCV14 may be administered to infants 6, 10, and 14 weeks of age in 3 doses. Streptococcus pneumoniae infection remains one of the leading causes of death among children under the age of five in India and in developing countries. BE's PCV14 Vaccine will help prevent invasive pneumococcal infection and save millions of lives worldwide.
BE's PCV14 contains 14 serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F). BE's PCV14 contains the largest number of serotypes in India and offers expanded protection against two new serotypes 22F and 33F. These new serotypes have been reported recently to be causing infections. In a Phase 3 infants trial BE's PCV14 was non-inferior to all the common serotypes present in the comparator's vaccine.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.